Mental health issues are well-documented, affecting nearly one billion people worldwide, with approximately 260 million residing in the WHO South-East Asia Region. Insufficient investment in mental health services and the healthcare workforce has led to significant treatment gaps in the region, a situation further worsened by the COVID-19 pandemic. Global estimates indicate the WHO South-East Asia Region accounts for around 27 per cent of all cases of depression and 23 per cent of all cases of anxiety.
Despite its inclusion in the Sustainable Development Goals (SDGs), only 2 per cent of total government health expenditure and 1 per cent of global development assistance for health are dedicated to mental health, according to the WHO’s Mental Health Atlas 2020.
Mental illness presents a significant health and socioeconomic burden, accounting for over 20 per cent of total Years Lived with Disability (YLDs) and 9.3 per cent of Disability-Adjusted Life Years (DALYs) in the Asia-Pacific region. As per a report by The Royal Australian and New Zealand College of Psychiatrists (2016), even advanced economies like Australia and New Zealand face GDP deficits of 3.5 per cent and 5 per cent, respectively, linked to mental illness. Furthermore, it is estimated that by 2030, mental illness will result in a loss of $11 trillion in economic growth for India and China alone, according to a report ‘Provision for Supporting People with Mental Illness: A Comparison of 15 Asia-Pacific Countries,’ prepared by The Economist Intelligence Unit (EIU) and sponsored by Janssen Asia Pacific.
To address these growing concerns, policymakers and health systems across the region are taking a note. Various countries have developed national strategic plans and made investments to strengthen mental healthcare.
Denne historien er fra October 2024-utgaven av BioSpectrum Asia.
Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.
Allerede abonnent ? Logg på
Denne historien er fra October 2024-utgaven av BioSpectrum Asia.
Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.
Allerede abonnent? Logg på
Promega unveils GloMax Galaxy Bioluminescence Imager for illuminating protein dynamics in real time
US-based Promega Corporation, a life-sciences research partner dedicated to providing intuitive tools that empower scientists to innovate, has unveiled the new GloMax Galaxy Bioluminescence Imager.
Singleron and Bioscreen to enhance access to single cell multi-omics solutions for Indian researchers
Singleron Biotechnologies, a leading innovator in single cell multi-omics solutions, has announced a strategic partnership with Bioscreen, a renowned distributor of advanced life science products in India.
Eppendorf brings CO2 incubator shaker with integrated 180 °C sterilisation routine
Eppendorf has announced the launch of a CO2 incubator shaker with integrated 180 °C sterilisation routine.
Waters introduces new bioseparations tools to improve development of RNA-based vaccines using LC-MS analysis
US-based Waters Corporation has introduced a comprehensive set of sample preparation enzymes, reagents, and waters_connect software that simplify sequence and modification confirmation of large molecule RNA therapeutics using liquid chromatography-mass spectrometry (LCMS) analysis.
Singapore designs novel gene therapy offering hope for epilepsy patients
Researchers from the Yong Loo Lin School of Medicine, National University of Singapore are working on a therapy that holds potential in treating patients with epilepsy, a neurological disorder defined by recurring seizures due to abnormal brain activity.
Spider venom heart drug moves to clinical trials in Australia
A University of Queensland (UQ)-led project in Australia to develop the first-ever drug to treat heart attack and protect donor hearts will move to human clinical trials, after receiving $17.8 million in funding from the Medical Research Future Fund (MRFF).
India develops portable ultrasound scanner for sports injury diagnosis
A team of researchers at the Indian Institute of Technology Madras (IIT-M) has developed an indigenous portable Point-of-CareUltrasound (POCUS) Scanner for sports injury diagnosis and management.
Integris appoints medtech veteran Probir Das as new CEO
Integris Healthcare, a global diversified medical technology company, has announced the appointment of Probir Das as Chief Executive Officer (CEO). He will join effective November 2024 and will be based in New Delhi.
Clarity Pharma promotes Michelle Parker to CEO
Australia-based Clarity Pharmaceuticals has announced the appointment of Michelle Parker as Chief Executive Officer (CEO), effective from October 11, 2024.
Dr Makoto Sugita steps in as President of Nxera Pharma Japan
Nxera Pharma Co., formerly known as Sosei Group or Sosei Heptares, has announced the appointment of Dr Makoto Sugita, as President of Nxera Pharma Japan, and Executive Officer, Executive Vice President and Chief Medical Officer (CMO) of Nxera Pharma.